Initial testing (stage 1) of the PARP inhibitor BMN 673 by...

Pediatric Blood & Cancer 2015 / 01 Vol. 62; Iss. 1

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673

Smith, Malcolm A., Hampton, Oliver A., Reynolds, C. Patrick, Kang, Min H., Maris, John M., Gorlick, Richard, Kolb, E. Anders, Lock, Richard, Carol, Hernan, Keir, Stephen T., Wu, Jianrong, Kurmasheva,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
62
Language:
english
Journal:
Pediatric Blood & Cancer
DOI:
10.1002/pbc.25201
Date:
January, 2015
File:
PDF, 1.08 MB
english, 2015
Conversion to is in progress
Conversion to is failed